Analyst Price Target is $52.00
▲ +134.66% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $52.00, with a high forecast of $80.00 and a low forecast of $38.00. The average price target represents a 134.66% upside from the last price of $22.16.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in Castle Biosciences. This Buy consensus rating has held steady for over two years.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.